$191.38
0.700.37%
At close: May 6, 5:00 PM EST
$190.00
-0.68-0.36%
Pre-Market: 7:34 AM EST
Biogen Inc Stock Guidance
BIIBNASDAQ
Biogen (BIIB) last issued guidance on April 29, 2026 for fiscal year 2026. The company guided earnings per share in the range of $14.25 - $15.25, compared to a consensus EPS estimate of $15.59.
Compared to prior guidance, Biogen lowered its EPS outlook from a previous range of $15.25 - $16.25.
Biogen has issued 16 guidance updates between July 20, 2022 and April 29, 2026. During this period, the company raised its outlook 6 times and lowered it 6 times, providing investors with insight into management's evolving expectations.
Latest Guidance Date
Apr 29, 2026
Guidance Period
Full Year 2026
EPS Guidance Range
$14.25 - $15.25
Biogen Guidance History
Review all historical guidance issued by Biogen, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for Biogen (BIIB)?
The most recent guidance for Biogen (BIIB) was reported on April 29, 2026 for the fiscal year 2026. The company provided earnings per share guidance in the range of $14.25 to $15.25, compared to the estimated EPS of $15.59.
What EPS range did Biogen (BIIB) guide for?
Biogen (BIIB) guided EPS in the range of $14.25 to $15.25 for the fiscal year 2026. The consensus analyst EPS estimate is $15.59.
What revenue range did Biogen (BIIB) guide for?
Biogen (BIIB) guided revenue in the range of $9.68B to $9.77B for the fiscal year 2025.
Did Biogen (BIIB) raise or lower guidance?
Biogen (BIIB) lowered its EPS guidance from a prior range of $15.25 - $16.25 to $14.25 - $15.25 for the fiscal year 2026.
When did Biogen (BIIB) last issue guidance?
Biogen (BIIB) last issued guidance on April 29, 2026 for the fiscal year 2026.
